InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
其他已披露买入
1
已披露卖出
1
T+90 胜率
0%
T+90 平均收益
-6.1%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the full record of transactions filed by New Enterprise Associates 15, L.P.. Director active across 10 companies, notably Eargo, Inc.. In total, 17 filings have been published. Split: 1 buy · 1 sell. Total volume traded: €9.8m. Activity tracked since 24 May 2021. The latest transaction was filed on 2 October 2025 (X). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to New Enterprise Associates 15, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
189,195 股@ US$0.01100.0% 占其流量Common StockSEC:0001193125-25-232128:0
3,333,000 股Common StockSEC:0000950170-25-038280:0
38,183,023 股Class A Common StockSEC:0001209191-23-043249:0
2,000,000 股0Common StockSEC:0001209191-22-062501:0
11,691,864 股0Common StockSEC:0001209191-22-057907:0
3,952,957 股0Common StockSEC:0001209191-22-054286:0
312,500 股@ US$16.000.13% mcap100.0% 占其流量Common StockSEC:0001209191-22-038994:0
标准退出：2022年9月19日 (T+90)
926,619 股@ US$5.8036100.0% 占其流量Common StockSEC:0001209191-22-032835:0
21,794,173 股0Class A Common StockSEC:0001209191-22-027244:0
4,849,429 股0Common StockSEC:0001209191-22-008192:0
21,794,173 股0Class A Common StockSEC:0001209191-22-006141:0
724,800 股0Class A Common StockSEC:0001209191-21-064208:0
724,800 股0Class A Common StockSEC:0001209191-21-062097:0
55,055,000 股Common StockSEC:0001209191-21-049424:0
10,601,925 股Common StockSEC:0001209191-21-044186:0
9,000,000 股0Class A Common StockSEC:0001209191-21-039483:0
2,000,000 股0Common StockSEC:0001209191-21-035932:0
17 条申报中的 17 条
About New Enterprise Associates 15, L.P.
New Enterprise Associates 15, L.P. is a declarant with 17 filings in total. In the recent sampled filings, the period runs from 2021-05-26 to 2025-10-06, with EUR 4,747,150 of purchases and EUR 5,010,481 of sales, and the companies involved include Robinhood Markets, Inc., Arcellx, Inc., IonQ, Inc., NeueHealth, Inc., Senti Biosciences, Inc., and Berkshire Grey, Inc.
